Oxaliplatin-related neurotoxicity

How and why?

Lara Maria Pasetto, Mario Rosario D'Andrea, Elena Rossi, Silvio Monfardini

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

In early clinical trials, oxaliplatin has demonstrated significant activity against colorectal cancer in combination with 5-fluorouracil (5-FU) and folinic acid (FA), both in metastatic as in radically resected disease. The drug differs from the other two most important platinum compounds (cisplatin and carboplatin) for the absence of nephrotoxicity or for the reduced drug-induced ototoxicity. During its administration, two different types of neurological symptoms can be experienced: the first one occurs during or immediately after the end of the infusion and it appears as a transient peripheral sensory neuropathy manifesting as paresthesias and dysesthesia in the extremities sometimes accompanied by muscular contractions of the extremities or the jaw (triggered or enhanced by exposure to cold). The second one occurs after long-term administration of oxaliplatin presenting with deep sensory loss, sensory ataxia and functional impairment (similar to those observed with cisplatin). This type of neurotoxicity is usually late-onset and correlated with the cumulative-dose of oxaliplatin. The aim of this review is to analyse the mechanism underlying induction of neurotoxicity and the possible treatments to prevent and to treat it.

Original languageEnglish
Pages (from-to)159-168
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume59
Issue number2
DOIs
Publication statusPublished - Aug 2006

Fingerprint

oxaliplatin
Paresthesia
Cisplatin
Extremities
Platinum Compounds
Leucovorin
Carboplatin
Peripheral Nervous System Diseases
Ataxia
Muscle Contraction
Jaw
Fluorouracil
Pharmaceutical Preparations
Colorectal Neoplasms
Clinical Trials

Keywords

  • Neurotoxicity
  • Oxaliplatin
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Oxaliplatin-related neurotoxicity : How and why? / Pasetto, Lara Maria; D'Andrea, Mario Rosario; Rossi, Elena; Monfardini, Silvio.

In: Critical Reviews in Oncology/Hematology, Vol. 59, No. 2, 08.2006, p. 159-168.

Research output: Contribution to journalArticle

Pasetto, LM, D'Andrea, MR, Rossi, E & Monfardini, S 2006, 'Oxaliplatin-related neurotoxicity: How and why?', Critical Reviews in Oncology/Hematology, vol. 59, no. 2, pp. 159-168. https://doi.org/10.1016/j.critrevonc.2006.01.001
Pasetto, Lara Maria ; D'Andrea, Mario Rosario ; Rossi, Elena ; Monfardini, Silvio. / Oxaliplatin-related neurotoxicity : How and why?. In: Critical Reviews in Oncology/Hematology. 2006 ; Vol. 59, No. 2. pp. 159-168.
@article{c793e34975db4ea38b096df07d089d47,
title = "Oxaliplatin-related neurotoxicity: How and why?",
abstract = "In early clinical trials, oxaliplatin has demonstrated significant activity against colorectal cancer in combination with 5-fluorouracil (5-FU) and folinic acid (FA), both in metastatic as in radically resected disease. The drug differs from the other two most important platinum compounds (cisplatin and carboplatin) for the absence of nephrotoxicity or for the reduced drug-induced ototoxicity. During its administration, two different types of neurological symptoms can be experienced: the first one occurs during or immediately after the end of the infusion and it appears as a transient peripheral sensory neuropathy manifesting as paresthesias and dysesthesia in the extremities sometimes accompanied by muscular contractions of the extremities or the jaw (triggered or enhanced by exposure to cold). The second one occurs after long-term administration of oxaliplatin presenting with deep sensory loss, sensory ataxia and functional impairment (similar to those observed with cisplatin). This type of neurotoxicity is usually late-onset and correlated with the cumulative-dose of oxaliplatin. The aim of this review is to analyse the mechanism underlying induction of neurotoxicity and the possible treatments to prevent and to treat it.",
keywords = "Neurotoxicity, Oxaliplatin, Review",
author = "Pasetto, {Lara Maria} and D'Andrea, {Mario Rosario} and Elena Rossi and Silvio Monfardini",
year = "2006",
month = "8",
doi = "10.1016/j.critrevonc.2006.01.001",
language = "English",
volume = "59",
pages = "159--168",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Oxaliplatin-related neurotoxicity

T2 - How and why?

AU - Pasetto, Lara Maria

AU - D'Andrea, Mario Rosario

AU - Rossi, Elena

AU - Monfardini, Silvio

PY - 2006/8

Y1 - 2006/8

N2 - In early clinical trials, oxaliplatin has demonstrated significant activity against colorectal cancer in combination with 5-fluorouracil (5-FU) and folinic acid (FA), both in metastatic as in radically resected disease. The drug differs from the other two most important platinum compounds (cisplatin and carboplatin) for the absence of nephrotoxicity or for the reduced drug-induced ototoxicity. During its administration, two different types of neurological symptoms can be experienced: the first one occurs during or immediately after the end of the infusion and it appears as a transient peripheral sensory neuropathy manifesting as paresthesias and dysesthesia in the extremities sometimes accompanied by muscular contractions of the extremities or the jaw (triggered or enhanced by exposure to cold). The second one occurs after long-term administration of oxaliplatin presenting with deep sensory loss, sensory ataxia and functional impairment (similar to those observed with cisplatin). This type of neurotoxicity is usually late-onset and correlated with the cumulative-dose of oxaliplatin. The aim of this review is to analyse the mechanism underlying induction of neurotoxicity and the possible treatments to prevent and to treat it.

AB - In early clinical trials, oxaliplatin has demonstrated significant activity against colorectal cancer in combination with 5-fluorouracil (5-FU) and folinic acid (FA), both in metastatic as in radically resected disease. The drug differs from the other two most important platinum compounds (cisplatin and carboplatin) for the absence of nephrotoxicity or for the reduced drug-induced ototoxicity. During its administration, two different types of neurological symptoms can be experienced: the first one occurs during or immediately after the end of the infusion and it appears as a transient peripheral sensory neuropathy manifesting as paresthesias and dysesthesia in the extremities sometimes accompanied by muscular contractions of the extremities or the jaw (triggered or enhanced by exposure to cold). The second one occurs after long-term administration of oxaliplatin presenting with deep sensory loss, sensory ataxia and functional impairment (similar to those observed with cisplatin). This type of neurotoxicity is usually late-onset and correlated with the cumulative-dose of oxaliplatin. The aim of this review is to analyse the mechanism underlying induction of neurotoxicity and the possible treatments to prevent and to treat it.

KW - Neurotoxicity

KW - Oxaliplatin

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=33746222050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746222050&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2006.01.001

DO - 10.1016/j.critrevonc.2006.01.001

M3 - Article

VL - 59

SP - 159

EP - 168

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -